Home Page
10:56:18 EDT Sat 23 May 2015
Enter Symbol
or Name

Q:AMBS - AMARANTUS BIOSCI INC - http://www.amarantus.com10:56:18 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AMBS - Qnot subscribed0.0501-0.0044-8.123,268.11,1188190.04735  0.0589  0.04250.20  0.0315:59:4207:0515 min RT 2¢

Recent Bulletins
Date ETSymbolTypeHeadline
2015-05-22 07:05AMBSNews ReleaseAmarantus Effects Capital Restructuring in Anticipation of National Exchange Listing
2015-05-21 07:05AMBSNews ReleaseAmarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
2015-05-20 07:05AMBSNews ReleaseAmarantus Reports First Quarter 2015 Financial Results and Business Overview
2015-05-19 07:05AMBSNews ReleaseAmarantus to Present at Two Upcoming Investor Conferences
2015-05-15 08:05AMBSNews ReleaseAmarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease
2015-05-14 13:35AMBSNews ReleaseAmarantus BioScience Holdings, Inc. – "MANF Begins its March Towards the Clinic"
2015-05-14 08:05AMBSNews ReleaseAmarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
2015-05-13 13:00AMBSNews ReleaseAmarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease
2015-05-11 10:18AMBSNews ReleaseIPOs & Transactions Week in Review: May 4 - 8
2015-05-11 08:35AMBSNews ReleaseAmarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis
2015-05-07 11:15AMBSNews ReleaseAmarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2015-05-05 08:05AMBSNews ReleaseAmarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
2015-04-29 07:05AMBSNews ReleaseAmarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
2015-04-27 07:05AMBSNews ReleaseAmarantus Closes $5 Million Preferred Stock Financing

Recent Trades - Last 10 of 819
Time ETExPriceChangeVolume